ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 123 filers reported holding ARBUTUS BIOPHARMA CORP in Q3 2022. The put-call ratio across all filers is 1.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $126,453 | -8.5% | 62,292 | +3.7% | 0.00% | 0.0% |
| Q2 2023 | $138,179 | -16.8% | 60,078 | +9.6% | 0.00% | 0.0% |
| Q1 2023 | $166,141 | +32.7% | 54,832 | +2.0% | 0.00% | 0.0% |
| Q4 2022 | $125,217 | +27.8% | 53,741 | +4.8% | 0.00% | 0.0% |
| Q3 2022 | $98,000 | -28.5% | 51,269 | +1.4% | 0.00% | 0.0% |
| Q2 2022 | $137,000 | +1.5% | 50,544 | +11.7% | 0.00% | 0.0% |
| Q1 2022 | $135,000 | -18.7% | 45,232 | +5.9% | 0.00% | 0.0% |
| Q4 2021 | $166,000 | -12.2% | 42,699 | -2.9% | 0.00% | 0.0% |
| Q3 2021 | $189,000 | +42.1% | 43,977 | +0.5% | 0.00% | – |
| Q2 2021 | $133,000 | +64.2% | 43,763 | +94.4% | 0.00% | – |
| Q1 2019 | $81,000 | -9.0% | 22,516 | -3.1% | 0.00% | – |
| Q4 2018 | $89,000 | -59.7% | 23,245 | -0.8% | 0.00% | -100.0% |
| Q3 2018 | $221,000 | +31.5% | 23,425 | +1.8% | 0.00% | 0.0% |
| Q2 2018 | $168,000 | – | 23,002 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,705,128 | $10,300,000 | 4.44% |
| RTW INVESTMENTS, LP | 5,666,754 | $15,754,000 | 0.59% |
| COWEN AND COMPANY, LLC | 926,200 | $2,575,000 | 0.22% |
| Hudson Bay Capital Management LP | 850,000 | $2,363,000 | 0.05% |
| LADENBURG THALMANN FINANCIAL SERVICES INC. | 1,774,915 | $4,934,000 | 0.03% |
| Point72 Asset Management, L.P. | 1,897,284 | $5,274,000 | 0.03% |
| 683 Capital Management, LLC | 77,368 | $215,000 | 0.02% |
| Secure Asset Management, LLC | 10,000 | $28,000 | 0.02% |
| Qube Research & Technologies Ltd | 166,138 | $462,000 | 0.01% |
| Verition Fund Management LLC | 174,455 | $485,000 | 0.01% |